ClinicalTrials.Veeva

Menu

Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China

X

Xi'an Jiaotong University

Status

Enrolling

Conditions

Acute COVID-19
COVID-19
Post-Acute COVID-19
Post-COVID-19 Syndrome

Treatments

Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum

Study type

Observational

Funder types

Other

Identifiers

NCT05745805
XJTU1AF2023-012

Details and patient eligibility

About

Our main objective is to analyze the development of physical impact, mental health and blood profile over follow-up time during the 1st wave of the COVID-19. Besides, we aim to establish a database of post-COVID-19 based on simultaneous cortico-spinal magnetic resonance imaging data to identify high-risk patients with long COVID and prevent the neurological symptoms evolution, optimize the tactics of management in China.

Full description

This is an observational, cross-sectional, and multicenter study. It will be performed at 9 public hospitals. Participants with confirmed cases of mild or moderate COVID-19 infection will complete the following programs at acute infection phase and after 3, 12 months for exploring biological mechanism and predictive biomarkers of post-COVID-19: 1) fill in the behavioral psychology scales, 2) submit blood samples at a local laboratory, 3) accept the simultaneous cortico-spinal magnetic resonance imaging scan. The uninfected healthy controls will complete the same programs as infected group mentioned above only at the time of inclusion. We will establish the simultaneous cortico-spinal magnetic resonance imaging database containing neuropsychological scales and blood parameters of post-COVID-19 in China.

Enrollment

600 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of mild Covid-19 (WHO criteria)/Confirmed diagnosis of moderate Covid-19 (WHO criteria)/Healthy people who have not had COVID-19

Exclusion criteria

History of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc. Participants with indication for MRI studies

Trial design

600 participants in 3 patient groups

Mild COVID-19 group
Description:
Confirmed diagnosis of mild Covid-19 (WHO criteria)
Treatment:
Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum
Moderate COVID-19 group
Description:
Confirmed diagnosis of moderate Covid-19 (WHO criteria)
Treatment:
Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum
Uninfected Healthy controls
Description:
Healthy people who have not had COVID-19
Treatment:
Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum

Trial contacts and locations

1

Loading...

Central trial contact

Xuan Niu, PhD; Ming Zhang, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems